Search research articles
Contact Us
Filters
Showing results (51-60 of 114) with videos related to
Page
of 12
Sort By:
Cancer Chemotherapy and Biological Response Modifiers
|
January 1, 1992
New anticancer agents
T D Brown, H A Burris, J R Eckardt, et al.
Archives of Dermatology
|
February 1, 1995
Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent
G C Zimmerman, J H Keeling, H A Burris, et al.
Gynecologic Oncology
|
November 28, 2006
A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies
M V Seiden, H A Burris, U Matulonis, et al.
Journal of the National Cancer Institute
|
January 5, 1994
Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitro
J R Eckardt, H A Burris, J G Kuhn, et al.
Journal of the National Cancer Institute
|
December 2, 1992
Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro
H A Burris, A R Hanauske, R K Johnson, et al.
Blood
|
May 16, 2000
Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma
J D Hainsworth, H A Burris, L H Morrissey, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery
|
April 29, 1998
Intratumoral cisplatin/epinephrine-injectable gel as a palliative treatment for accessible solid tumors: a multicenter pilot study
H A Burris, C L Vogel, D Castro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 1995
Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer
P M Ravdin, H A Burris, G Cook, et al.
Investigational New Drugs
|
April 6, 2006
A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane
J A Ajani, H Safran, C Bokemeyer, et al.
Cancer Chemotherapy and Biological Response Modifiers
|
January 1, 1993
New anticancer agents
G R Weiss, H A Burris, J R Eckardt, et al.
Page
of 12
Search research articles
Search
Showing results (51-60 of 114) with videos related to
Sort By:
Page
of 12
Cancer Chemotherapy and Biological Response Modifiers
|
January 1, 1992
New anticancer agents
T D Brown, H A Burris, J R Eckardt, et al.
Archives of Dermatology
|
February 1, 1995
Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent
G C Zimmerman, J H Keeling, H A Burris, et al.
Gynecologic Oncology
|
November 28, 2006
A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies
M V Seiden, H A Burris, U Matulonis, et al.
Journal of the National Cancer Institute
|
January 5, 1994
Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitro
J R Eckardt, H A Burris, J G Kuhn, et al.
Journal of the National Cancer Institute
|
December 2, 1992
Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro
H A Burris, A R Hanauske, R K Johnson, et al.
Blood
|
May 16, 2000
Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma
J D Hainsworth, H A Burris, L H Morrissey, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery
|
April 29, 1998
Intratumoral cisplatin/epinephrine-injectable gel as a palliative treatment for accessible solid tumors: a multicenter pilot study
H A Burris, C L Vogel, D Castro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 1995
Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer
P M Ravdin, H A Burris, G Cook, et al.
Investigational New Drugs
|
April 6, 2006
A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane
J A Ajani, H Safran, C Bokemeyer, et al.
Cancer Chemotherapy and Biological Response Modifiers
|
January 1, 1993
New anticancer agents
G R Weiss, H A Burris, J R Eckardt, et al.
Page
of 12